Haleon PLC Sponsored ADR $HLN Shares Bought by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lifted its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 18.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,441,178 shares of the company’s stock after buying an additional 1,589,494 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.23% of Haleon worth $105,560,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in HLN. Stance Capital LLC acquired a new position in shares of Haleon during the third quarter worth about $34,000. Geneos Wealth Management Inc. grew its position in shares of Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after buying an additional 1,203 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Haleon by 428.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after buying an additional 5,124 shares in the last quarter. Assetmark Inc. grew its position in shares of Haleon by 26.6% during the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock worth $60,000 after buying an additional 1,252 shares in the last quarter. Finally, Atlantic Union Bankshares Corp grew its position in shares of Haleon by 69.4% during the fourth quarter. Atlantic Union Bankshares Corp now owns 6,264 shares of the company’s stock worth $63,000 after buying an additional 2,567 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Finally, Argus raised Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of Haleon stock opened at $9.12 on Wednesday. The firm has a market capitalization of $40.37 billion, a P/E ratio of 23.37, a P/E/G ratio of 2.02 and a beta of 0.13. Haleon PLC Sponsored ADR has a 52 week low of $8.65 and a 52 week high of $11.28. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The firm’s 50 day moving average is $9.40 and its two-hundred day moving average is $9.92.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion during the quarter. Research analysts forecast that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.